John Case, MD
Urology · San Antonio, TXNPI 1396859039
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $924, 2.2 times the $422 reported in 2019. That places this record below the midpoint for urology clinicians in TX, where the typical reported total is $3,394.
Across 135 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$393
- Johnson & Johnson$267
- Astellas Pharma US Inc$249
- Endo Pharmaceuticals Inc.$207
- Blue Earth Diagnostics$172
- Novartis$143
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,876100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 16 | $393 |
| Johnson & Johnson | 14 | $267 |
| Astellas Pharma US Inc | 14 | $249 |
| Endo Pharmaceuticals Inc. | 9 | $207 |
| Blue Earth Diagnostics | 7 | $172 |
| Novartis | 6 | $143 |
| Pfizer | 9 | $140 |
| Myovant Sciences Inc. | 6 | $128 |
| Dendreon Pharmaceuticals LLC | 4 | $114 |
| Urogen Pharma, Inc. | 6 | $101 |
| AbbVie | 5 | $91 |
| Bayer | 5 | $89 |
| Tolmar Pharmaceuticals, Inc. | 4 | $85 |
| Medtronic | 4 | $77 |
| Procept Biorobotics Corporation | 2 | $76 |
| Olympus America Inc. | 2 | $75 |
| Myriad Genetic Laboratories, Inc. | 2 | $54 |
| Boston Scientific | 3 | $52 |
| Antares Pharma, Inc. | 4 | $49 |
| Accord Healthcare, Inc. | 2 | $42 |
| Integra Lifesciences Corporation | 1 | $39 |
| Vertex | 1 | $33 |
| Merck | 1 | $32 |
| Aytu Biopharma, Inc. | 2 | $30 |
| Philips North America LLC | 1 | $30 |
| Verity Pharmaceuticals Inc. | 1 | $29 |
| AstraZeneca | 1 | $26 |
| Urovant Sciences Inc | 1 | $20 |
| Tolmar, Inc. | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
How this compares
$2,876 in reported general payments places this provider in the 40th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 46 | $114,517 |
| MyrbetriqMirabegron | 132 | $111,428 |
| GemtesaVibegron | 46 | $39,169 |
| TestopelTestosterone | 26 | $32,650 |
| Testosterone Cypionate | 241 | $21,171 |
| Tamsulosin Hcl | 975 | $19,309 |
| Finasteride | 818 | $10,106 |
| Testosterone | 18 | $4,759 |
| Potassium Citrate ErPotassium Citrate | 26 | $3,338 |
| Trimethoprim | 45 | $3,134 |
| Tadalafil | 18 | $2,947 |
| ClomidClomiphene Citrate | 11 | $2,592 |
| Doxycycline Monohydrate | 145 | $2,328 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 54 | $1,509 |
| Cephalexin | 94 | $1,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $393 | $153,68692 claims |
| Astellas Pharma US IncMyrbetriq | $249 | $111,428132 claims |
| Endo Pharmaceuticals Inc.Testopel | $207 | $32,65026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 878 urology providers in Texas.
Other urology in San Antonio
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jose de la CerdaSan Antonio$278K
- Naveen KellaSan Antonio$84K
- Christopher CantrillSan Antonio$73K
- Robert SvatekSan Antonio$51K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.